Puma Biotechnology (PBYI)
Commercializes NERLYNX for HER2-positive breast cancer and develops alisertib.
Something off on this page? Send us feedback.
Commercializes NERLYNX for HER2-positive breast cancer, with all product revenue tied to that medicine and royalties from ex-U.S. sublicenses. A single reporting segment also carries alisertib, a Takeda-licensed aurora kinase A inhibitor in Phase II oncology studies.
Commercializes NERLYNX, oral neratinib, for certain HER2-positive breast cancers in the United States and receives royalties from partners selling the medicine outside the country. The operating model is narrow: one reporting segment, a field-based commercial footprint, and revenue derived through NERLYNX product sales, licenses, and royalties rather than a broad drug portfolio.
Develops alisertib under a Takeda license while studying additional oncology settings, including small cell lung cancer and hormone receptor-positive metastatic breast cancer. Execution depends on physician adoption in approved NERLYNX uses, partner reach in international markets, FDA-defined labels, and clinical progress for alisertib.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $93.9M · Total debt $4.8M · Total assets $192.7M · Shareholders' equity $138.5M
- Revenue
- $56.5M
- Operating income
- $7.6M
- Net income
- $8.2M
No dividends on record.
| Institutions | 75.18% | 38.81M shares | |
|---|---|---|---|
| 166 holders · as of Jun 30, 2026 | |||
| Insiders | 21.44% | 11.07M shares | |
| 12 holders · as of Sep 16, 2026 | |||
| Other | 3.38% | 1.74M shares | |
| remainder | |||
51.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alan H. AuerbachInsiderdirector, 10 percent owner, officer: President and CEO | 14.07% | 7.26M | filed Jul 8, 2026 |
Acorn Capital Advisors, LLCInstitution | 8.00% | 4.13M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.37% | 3.80M | as of Jun 30, 2026 |
Anders HoveInsider | 5.31% | 2.74M | filed Sep 1, 2023 |
American Century Companies IncInstitution | 4.49% | 2.32M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Troy Edward Wilson | director | −5,000 | $9.10 |
| Sep 14, 2026 | Alessandra Cesano | director | −62,150 | $9.12 |
| Jul 6, 2026 | Maximo F. Nougues | officer: Chief Financial Officer | −9,386 | $8.26 |
| Jul 6, 2026 | Douglas M. Hunt | officer: See Remarks | −8,460 | $8.26 |
| Jul 6, 2026 | Alan H. Auerbach | director, 10 percent owner, officer: President and CEO | −44,058 | $8.26 |
